Skip to main content
Premium Trial:

Request an Annual Quote

Morphosys Extends Research Agreement with Pharma Firm Shionogi

Premium

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

The agreement covers Shionogi's use of Morphosys' HuCal antibody platform for drug development research in exchange for annual user fees. Further financial details were not disclosed.

The project will be run on Morphosys' end by its AbD Serotec unit. Shionogi will have the right to use the company's HuCAL Platinum antibody library for research purposes at one of its research sites.

AbD Serotec uses its HuCAL – or Human Combinatorial Antibody Library – platform to generate monoclonal antibodies for research and diagnostic applications. The platform consists of a collection of several billion distinct fully human antibodies that, according to the company's website, allows for the rapid selection of antibodies with high affinity and specificity.

Morphosys and Shionogi first signed a license agreement for the use of the HuCAL platform in September 2005.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.